Michigan State University Parkinson Disease Clinical Center

这是密歇根州立大学（MSU）神经病学系成为 帕金森病神经保护临床试验联盟的临床中心。这个的目的 临床试验证明了一种或几种神经保护剂在减缓进展中的功效 帕金森病（PD）的一项大型、双盲、安慰剂对照临床试验。MSU帕金森 疾病临床中心将识别、招募和维持轻度早期PD患者（Hoehn & Yahr <2， 症状发作后5年内）。 该提案记录了经验丰富的 MSU的临床工作人员总的来说，主要研究者和密歇根州立大学神经病学系 平均每年有近700名PD患者就诊，约有125名新的PD患者。基于 直接病历审查数据显示，55%的新患者符合入选和排除标准，如果 包括服用对症药物的患者;如果服用对症药物，20%的患者符合标准 药物被排除在外。可能符合条件的大量病例反映了 密歇根州立大学神经病学系，这是一个大面积的初级和二级转诊的重点， 其他神经科医生服务相对不足的州。 密歇根州立大学在密歇根州的中心位置，加上分散的全州医疗 学校校园系统，是理想的最大病人招募。与地区建立关系 神经学家，当地的支持团体和密歇根州帕金森基金会，首屈一指的全州PD 支持组织，将加强在密歇根州立大学独特的招聘基地。与香港大学合作 密歇根州，以及区域神经学家和运动障碍专科提供者，将促进 有效和全面的患者确认。具有运动障碍专业知识的MSU神经学家 将招募并随访患者。密歇根州立大学以前的经验，大型，纵向临床试验提供了一个 在类似的神经系统多中心研究中，在招募、保留和数据采集方面有良好的记录 疾病MSU是一个最佳的环境非常成功的参与帕金森病 神经保护临床试验。

This is an application for the Michigan State University (MSU) Department of Neurology to become a clinical center in the Parkinson Disease Neuroprotection Clinical Trial consortium. The objective of the this clinical trial is demonstrate the efficacy of one or several neuroprotective agents in slowing the progression of Parkinson Disease (PD) in a large, double blind, placebo-controlled clinical trial. The MSU Parkinson Disease Clinical Center will identify, enroll and maintain patients with mild, early PD (Hoehn & Yahr <2, within 5 years of symptom onset) in the pilot and Phase III trial components of this multicenter clinical trial. This proposal documents the outstanding patient recruitment and retention potential of the experienced clinical staff at MSU. Collectively, the primary investigators and the Department of Neurology at MSU have an average of nearly 700 PD patient visits and see approximately 125 new PD patients per year. Based on data from direct chart review, 55% of the new patients would meet the inclusion and exclusion criteria if patients taking symptomatic medications are included; 20% would meet criteria if those taking symptomatic medications were excluded. The large pool of potentially eligible cases reflects the referral pattern for the Department of Neurology at MSU, which is the focus of primary and secondary referrals from a large area of the state that is relatively underserved by other neurologists. The central location of MSU within the state of Michigan, combined with the dispersed statewide medical school campus system, is ideal for maximal patient recruitment. Established relationships with area neurologists, local support groups and with the Michigan Parkinson Foundation, the premier statewide PD support organization, will enhance the unique recruitment base at MSU. Collaboration with the University of Michigan, as well as regional neurologists and movement disorders subspecialty providers, will foster efficient and comprehensive patient ascertainment. MSU neurologists with expertise in movement disorders will enroll and follow patients. MSU's previous experience with large, longitudinal clinical trials provide a proven track record in recruiting, retention and data acquisition in similar multi-center studies of neurological disease. MSU is an optimum environment highly successful participation in the Parkinson Disease Neuroprotection Clinical Trial.